News

GODDYN supports Celyad

GODDYN starts a collaboration with Celyad for supporting the development of Celyad’s legal strategy and for the provision of legal services. Celyad SA (Euronext Brussels and Paris, and NASDAQ: CYAD) is a biopharmaceutical company, specialized in cell therapy, that is developing landmark technologies aimed at treating severe diseases with poor prognosis. Celyad’s scientific approach is inspired by the natural mechanisms that are used by the body to fight disease. Celyad…

Read More

Bart GODDYN speaker at IP World Summit 2017

Bart GODDYN served as speaker for the IP World Summit 2017 conference on 25-27 September 2017 in Amsterdam, The Netherlands. The IP World Summit, formerly known as Global Patent Congress, is a one-stop shop for IP leaders offering a mix of thought provoking and practical sessions now covering a range of approaches to IP protection and monetisation, including patents, trade secrets, designs, copyright, licensing and trademarks. The IP World Summit…

Read More

Legal IQ interview about trade secrets

Bart GODDYN was interviewed by Legal IQ (a division of IQPC) about trade secrets and the new European Trade Secrets Directive. Below is the transcript of the interview. Bart will be speaking about this topic at the IP World Summit in Amsterdam on the 25-27 of September 2017. Check out the agenda for more information: https://ipworldsummit.iqpc.com.   Firstly, could you summarise what a trade secret is and why someone would choose…

Read More

Bart GODDYN speaker at IICJ Conference 2017

Bart GODDYN served as panel moderator and speaker for the fifth International In-House Counsel Journal (IICJ) Conference on 28 March 2017 at the Law Society in London, UK. Senior in-house counsel drawn from all business sectors across Europe and North America attended the conference. The conference provided delegates with an ideal opportunity to discover the strategies and solutions companies are adopting across the full range in-house counsel management issues. Bart…

Read More

GODDYN joined FlandersBio

We have great pleasure in announcing that GODDYN has become part of FlandersBio’s membership list. FlandersBio is the networking organization for the life sciences sector in Flanders, a dynamic non-profit, fee-based organization with currently more than 340 members.

GODDYN assists TiGenix in deal with Takeda

GODDYN assists TiGenix in a licensing transaction with Takeda for TiGenix’s product Cx601. TiGenix NV (Euronext Brussels: TIG) and Takeda Pharmaceutical Company Limited (TSE: 4502) have entered into an exclusive ex-U.S. license, development and commercialization agreement for TiGenix’s product Cx601, a suspension of allogeneic adipose-derived stem cells (eASC) injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn’s disease. TiGenix will receive an upfront cash payment of…

Read More

GODDYN advises TiGenix on Sepcell project

GODDYN advises TiGenix on TiGenix’s role as coordinator of the SEPCELL project. TiGenix (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms. TiGenix announced on 2 November 2015 that the SEPCELL project has been awarded a €5.4M grant from the European Commission under Horizon 2020, the European Union’s framework programme for research and innovation, to conduct a clinical Phase Ib/IIa trial…

Read More

GODDYN wins 2015 Global Law Experts Award

GODDYN has great pleasure in announcing that Bart GODDYN, who is the firm’s managing partner, has been chosen as the 2015 winner in the category ‘Transactions Lawyer of the Year in Belgium’ by Global Law Experts (GLE).   The award rewards excellence of GODDYN’s transactional and advisory work in the area of Intellectual Property and R&D.   Over recent months, GLE has conducted its extensive nomination and research process for…

Read More

Release of book on copyright for media professionals

GODDYN has great pleasure in announcing the publication of a book on copyright for media professionals by Wim CRIEL (Roularta Media Group). The book, to which Bart GODDYN has contributed, was released on a press conference today. “It has been an honour, a privilege and a pleasure to have contributed to the writing of Wim’s book. The publication is the result of Wim’s remarkable perseverance to have the complex matter…

Read More

GODDYN advises TiGenix on agreement with Lonza

GODDYN has advised TiGenix (Euronext Brussels: TIG) on an agreement with Lonza for the manufacture of stem cell-based treatment of complex perianal fistulas in Crohn’s disease. TiGenix is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from allogeneic expanded adipose-derived stem cells (eASCs) in inflammatory and autoimmune diseases. Lonza is a global leader in biological and cell therapy manufacturing. TiGenix and Lonza announced today an agreement for…

Read More